A few months ago, results of a preliminary study on the effect of CBD on the liver were released by Validcare. The company then released a separate report on the use of CBD among Americans, which was carried out in collaboration with Cannabis Business Experts (“CBE”), a marketing research firm.
The results of the preliminary study demonstrated no evidence of liver toxicity among users of cannabidiol, or CBD. Additionally, most of those who participated in the study recorded increased perceptions of overall wellness with the use of cannabidiol in the study with CBE.
More than one thousand users of CBD in the United States took part in the joint study, which included more than 800 users who had participated in the liver study.
The investigators looked at different information about CBD uses, such as CBD usage frequency and amount; user weight, sex and age; and interactions with other drugs, including tobacco, alcohol, nutritional supplements, over-the-counter medicines and prescription drugs.
In the press release to announce the report, CBE asserted that the study helped to better understand how general wellness perceptions changed with the use of CBD. In addition, Ashley Grace, the company’s co-founder, noted that CBD users reported an enhanced perception of their personal wellness.
All the study participants had used CBD prior to the study. This was confirmed by researchers who asserted that the consumers were customers of the CBD companies that sponsored the study.
The researchers discovered that more than 12% of the cannabidiol users made up about 30% of the sales volume in the category. Grace stated that this was surprising as it didn’t align with the rule that 20% of consumers made up 80% of the volume in business.
Grace, who was also HempFusion and Charlotte’s Web’s founding chief marketing officer, noted that individuals who consumed tobacco and/or alcohol used cannabidiol differently in comparison with those who hadn’t used these other substances. She added that it was important to understand that companies operating in the sector would sometimes record variations, which would be brought about by the number of heavy users in their consumers.
The research was sponsored by the following CBD firms: SunMed CBD, Medterra CBD, Kannaway, Infinite CBD, HempFusion, Global Widget, Columbia Care, Charlotte’s Web, CBD American Shaman, CBDistillery, Care by Design, Boulder Botanical and Bioscience Labs and Asterra Labs.
Other companies, including XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), are conducting more rigorous clinical studies aimed at ascertaining the efficacy of formulations containing various cannabis compounds. If the trials are a success, regulatory approval is likely to follow, and patients would benefit from those products.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://cnw.fm/XPHYF
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.